|
|
Clinical effect of laparoscopic radical prostatectomy combined with neoadjuvant hormonal therapy for T3N0M0 prostate cancer |
JIANG Qi-qi1 YE Lie-fu2▲ WU Xiang2 LIU Zhi-hua1 |
1.Department of Urology,Fujian Provincial Jinshan Hospital,Fujian Province,Fuzhou 350028,China;
2.Department of Urology,Fujian Provincial Hospital,Fujian Province,Fuzhou 350001,China |
|
|
Abstract Objective To explore the clinical effect of laparoscopic radical prostatectomy combined with neoadjuvant hormonal therapy(NHT)for T3N0M0 prostate cancer.Methods The clinical data of 72 patients with T3N0M0 stage prostate adenocarcinoma admitted to Urology of Fujian Provincial Hospital and Fujian Provincial Jinshan Hospital from January 2010 to July 2019 were retrospectively analyzed.They were divided into the experimental group(38 cases)and the control group(34 cases)according to whether NHT was used.The experimental group were treated by laparoscopic radical prostatectomy combined with NHT.The control group were treated by laparoscopic radical prostatectomy.The operation time,intraoperative blood loss,serum prostate specific antige(PSA)level,postoperative incision margin positive,rectal injury,urinary incontinence,anastomotic leakage and erectile dysfunction were compared between the two groups.Results There was no significant difference in the operation time between the two groups(P>0.05).There was no significant difference in the amount of bleeding between the two groups(P>0.05).The number of positive cases in the experimental group was less than that in the control group,the difference was statistically significant(P<0.05).The serum PSA level in the experimental group was lower than that in the control group,the difference was statistically significant(P<0.05).There were no significant differences in the number of rectal injury,urinary incontinence,urinary fistula and erectile dysfunction between the two groups(P>0.05).Conclusion Laparoscopic radical prostatectomy combined with NHT in the treatment of T3N0M0 stage prostate cancer is safe and effective,which could significantly reduce the positive rate of surgical margin,and have no effect on the operation difficulty and postoperative complications,which is worthy of clinical promotion.
|
|
|
|
|
[1] |
周雪丽.前列腺癌幸存者心理痛苦和生存质量的相关性研究[D].天津:天津医科大学,2019.
|
[2] |
Siegel RL,Miller KD,Jemal A.Cancer statistics,2016.[J].CA Cancer J Clin,2016,66(1):7-30.
|
[3] |
李斌,林哲,胡渊.间断抗雄激素联合手术去势治疗晚期前列腺癌的疗效分析[J].中国现代医学杂志,2019,29(6):92-95.
|
[4] |
王宁,刘硕,杨雷,等.2018 全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2019,5(1):87-97.
|
[5] |
Cornford P,Bellmunt J,Bolla M,et al.EAU-ESTRO-SIOG Guidelines on Prostate Cancer.Part Ⅱ:Treatment of Relapsing,Metastatic,and Castration-Resistant Prostate Cancer[J].Eur Urol,2017,71(4):630-642.
|
[6] |
Mottet N,Bellmunt J,Bolla M,et al.EAU-ESTRO-SIOG Guidelines on Prostate Cancer.Part 1:Screening,Diagnosis,and Local Treatment with Curative Intent[J].Eur Urol,2017,71(4):618-629.
|
[7] |
赵晓智,杨荣,邱雪峰,等.美国临床肿瘤学会2019年泌尿生殖系统癌症研讨会(ASCO-GU 2019)会议专题纪要[J].泌尿外科杂志(电子版),2019,11(1):46-62.
|
[8] |
曹德宏,柳良仁,魏强,等.前列腺癌的治疗研究进展[J].华西医学,2017,32(2):277-281.
|
[9] |
Lancee M,Tikkinen KAO,de Reijke TM,et al.Guideline of guidelines:primary monotherapies for localised or locally advanced prostate cancer[J].BJU International,2018,122(4):535-548.
|
[10] |
郭程浩,丁雪飞.前列腺癌的局部治疗进展[J].临床泌尿外科杂志,2020,35(6):491-496.
|
[11] |
那彦群,孙光,叶章群,等.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2009.
|
[12] |
董柏君,贺大林,李名钊,等.前列腺癌经典内分泌治疗安全共识[J].现代泌尿外科杂志,2018,23(4):248-258.
|
[13] |
Taneja,Samir S.Re:Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer:Long-Term Survival Analysis of the Randomized Phase ⅢE3805 CHAARTED Trial[J].J Clin Oncol,2018,195(1):94-96.
|
[14] |
曹志骏.新辅助内分泌治疗在局部高危前列腺癌治疗中的应用和效果分析[D].苏州:苏州大学,2017.
|
[15] |
高强,张保,史玉强,等.新辅助内分泌治疗后行腹腔镜下前列腺癌根治术治疗局部晚期前列腺癌的临床分析[J].现代泌尿生殖肿瘤杂志,2018,10(3):145-148.
|
[16] |
齐浩.新辅助内分泌治疗临床效果评估[D].济南:山东大学,2019.
|
[17] |
梁文立,周立群.前列腺癌的新辅助内分泌治疗[J/CD].中华临床医师杂志:电子版,2009(3)4:546-553.
|
[18] |
陈晓霞,王彬彬,顾锡冬.乳腺癌辅助内分泌治疗的不良反应及其中医药治疗探讨[J].中国现代医生,2019,57(4):157-160.
|
[19] |
陈石景.腹腔镜下前列腺癌根治术联合新辅助内分泌治疗对T3N0M0期前列腺癌患者临床效果分析[J].当代医学,2019,25(35):12-14.
|
|
|
|